MARKET WIREStockInvest.us • 20h ago
Neuronetics Stock Price Forecast. Should You Buy STIM?StockInvest.us report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
Why STIM Stock dropped -8.44% Today — RQD Quant Desk Flash
$2.06 -8.44% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.02
Neuronetics Inc. (STIM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $171.4M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on STIM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is STIM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Neuronetics Inc. (NASDAQ: STIM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.06 (-8.44% 1D, market cap $171.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STIM ranks #862 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does STIM compare to PDEX and KTWO in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), STIM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 48.5%, and ROIC of -35.0%. By comparison, PDEX (Pro-Dex Inc.) holds a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for STIM?
▼
Per STIM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001227636), Neuronetics Inc. generated $149.2M in revenue (+99.2% YoY), -$39.0M in net income, and -$20.4M in free cash flow against $141.6M in total assets and $65.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.02 (-1.71%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-13.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for STIM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY STIM SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (32% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+6/20 pts (21% of score)
Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.99-0.5% Next Q
20
Q2 (-2Q)Grade E$1.98+10.6% Next Q
23
Q3 (-1Q)Grade E$2.19-5.9% Next Q
25
CurrentGrade E$2.06-10% Hist 90D α
28
Trajectory: E (20) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a STIM Turnaround Squeeze
While STIM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.50) and Max Pain ($2.16) forces dealer call-delta covering toward $3.61.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $STIM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “STIM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why STIM Stock dropped -8.44% Today — RQD Quant Desk Flash
Neuronetics Inc. (STIM) dropped -8.44% to $2.06, trading at 48% of its 52-week range ($0.8 – $3.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 48% of its 52-week range ($0.8 – $3.44) with RSI-14 at 49.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.06 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 48.5% gross margin and $0 annual free cash flow.
Live STIM Headlines & Catalysts
MARKET WIREYahoo! Finance Canada • 23h ago
Neuronetics, Inc. (STIM) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Neuronetics: Transforming From Device Manufacturer To Psychedelic Infrastructure (STIM)Seeking Alpha report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus ViewsYahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREad-hoc-news.de • 1d ago
Neuronetics schedules November 4 results for Neuronetics stockad-hoc-news.de report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue EstimatesYahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 12d ago
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference CallMALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook netwo
MARKET WIREYahoo • 13d ago
Integra LifeSciences (IART) Surpasses Q3 Earnings EstimatesIntegra (IART) delivered earnings and revenue surprises of +5.36% and -0.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring STIM)
- ✓Walkthrough of STIM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
STIM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.98%🛡️ HOLDING TREND SUPPORT
2026-11-03O $2.38H $2.38L $2.06C $2.06VOL 1.09M
RES: $4.01SUP: $1.95SMA50: $2.50SMA200: $1.88
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
STIM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +99.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on STIM today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for STIM. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for STIM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (STIM)
Health Care Rank #862 of 1016
⚔️ PDEX vs STIM Full Matrix →
1. Head-to-Head Health Care Peer Comparison (STIM vs. PDEX, KTWO, KRMD, UTMD)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuronetics Inc. (STIM) ranks #862 by composite RQD confidence (28/100, grade E) and #593 by equity capitalization ($171.4M). Within this direct 5-issuer industry benchmark cohort, PDEX leads on earnings valuation at 22.2x trailing P/E, while UTMD leads on capital efficiency and profitability with 26.9% ROIC and 57.1% gross margin. UTMD currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with STIM at 28/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| STIM
ACTIVE
Neuronetics Inc. | E | 28/100 | — | 48.5% | -35.0% | -8.44% | $171.4M | Benchmark Subject |
| PDEX Pro-Dex Inc. | D+ | 54/100 | 22.2x | 29.3% | 23.2% | -0.88% | $186.1M | /pdex-vs-stim → |
| KTWO K2 Capital Acquisition Corporation Class A Ordinary Share | D+ | 56/100 | — | — | — | +0.20% | $202.2M | /ktwo-vs-stim → |
| KRMD KORU Medical Systems Inc. | D- | 41/100 | — | 62.3% | -28.7% | +2.01% | $138.1M | /krmd-vs-stim → |
| UTMD Utah Medical Products Inc. | C | 62/100 | — | 57.1% | 26.9% | +3.64% | $216.7M | /utmd-vs-stim → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001227636In its most recent audited fiscal period (FY2025, filed 2025-12-31), Neuronetics Inc. (STIM) reported GAAP revenue of $149.2M (+99.2% vs. FY2024 revenue of $74.9M , and +109.1% cumulative change since FY2023) , GAAP net income of -$39.0M, operating cash flow of -$20.4M, and free cash flow of -$20.4M (+34.2% YoY). On the balance sheet, STIM closed FY2025 with $141.6M in total assets against $65.8M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $149.2M | -$39.0M | -$20.4M | -$20.4M | $141.6M | $65.8M |
| FY2024 (FY) | 2024-12-31 | $74.9M | -$43.7M | -$31.0M | -$31.0M | $140.9M | $55.2M |
| FY2023 (FY) | 2023-12-31 | $71.3M | -$30.2M | -$32.0M | -$32.0M | — | — |
3. STIM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs STIM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Neuronetics Inc. (NASDAQ: STIM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $2.06 (-8.44% 1D, market cap $171.4M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 6/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, STIM ranks #862 in composite RQD confidence.
How does STIM compare to PDEX and KTWO in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), STIM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of 48.5%, and ROIC of -35.0%. By comparison, PDEX (Pro-Dex Inc.) holds a D+ grade (54/100 RQD, P/E 22.2x, ROIC 23.2%, cap $186.1M) and KTWO (K2 Capital Acquisition Corporation Class A Ordinary Share) posts a D+ grade (56/100 RQD, P/E N/A, ROIC —, cap $202.2M). Among the 5-stock peer group, PDEX leads on earnings multiple (22.2x) while UTMD leads on capital efficiency (26.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for STIM?
Per STIM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001227636), Neuronetics Inc. generated $149.2M in revenue (+99.2% YoY), -$39.0M in net income, and -$20.4M in free cash flow against $141.6M in total assets and $65.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is STIM trading relative to its 50-day, 200-day, and 52-week technical levels?
STIM last traded at $2.06 (-8.44% on volume of 976,157 shares), positioning the stock -17.60% below its 50-day simple moving average ($2.50) and +9.57% above its 200-day simple moving average ($1.88). Across its 52-week range of $0.80 to $3.44, STIM sits at the 47.7% percentile with a 14-day RSI of 49.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.80 to $2.32).
ROARABLE RATING BRIEF • RQD 28/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
STIM — Neuronetics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:41:48Z
1. Roarable Rating Brief: What This Means to a Prospective Investor
The STIM scores 30 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:
- Fundamental Cash Engine: 5 / 20 — ROIC of -35% and FCF yield of -11.25%. The cash-generation pillar is the weakest contributor to the score, indicating the business is consuming rather than producing cash on this measure.
- Whale 13F Flow: 11 / 20 — Reflects institutional accumulation and options positioning. This is the strongest pillar, though still below half of its maximum.
- Insider Conviction: 3 / 20 — Reflects SEC Form 4 and Congressional PTR cluster flow. This is among the lowest pillar scores and signals limited insider-side confidence per the rating's inputs.
- Macro Regime Fit: 5 / 20 — Beta of 1.0 and sector sensitivity. The score suggests the stock's macro positioning offers little favorable regime alignment.
- Forensic Balance Sheet: 6 / 20 — Altman Z of 0.2, Piotroski F of 5/9, and Debt/Equity of 2.94. And rating inputs, these readings point to elevated balance-sheet and solvency risk.
For a prospective investor evaluating the stock today, the rating's composition matters: the weakest pillars (cash engine, insider conviction, balance sheet, macro fit) all point in the same direction, while the institutional-flow pillar is the only one with meaningful support. Upside drivers would need to come from a reversal in cash generation or balance-sheet repair, neither of which is evidenced in the source data. The stock's 52-week range of $0.8 - $3.44 against a current price of 2.38 shows substantial price volatility, which the rating treats as a risk characteristic rather than a signal of value.
2. Business Model, Unit Margins & SEC Financial Trajectory
Neuronetics Inc. (STIM) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The profile describes the company as having a market capitalization of $0.2B. FY 2025 revenue was $149.2M. Specific product lines, customer base, and revenue model details are —
Gross margin is 48.5%, operating margin is -21.1%, and net margin is -26.1%, with ROIC of -35%. Per the RQD rating, the Altman Z-Score is 0.2 and the Piotroski F-Score is 5/9. The balance sheet shows a Debt/Equity ratio of 2.94 per the rating inputs. Reported operating and net losses persist across all three periods shown.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Whale 13F Flow pillar at 11/20 is the rating's strongest component, reflecting institutional accumulation and options positioning. With Fundamental Cash Engine at 5/20 (ROIC -35.0%, FCF yield -11.25%) and Institutional Whale Flow at 9/20, sustained execution supports upside toward the top of the $0.80 – $3.44 52-week range.
- 🐻 Primary Bear Case: Altman Z of 0.2 and Debt/Equity of 2.94 sit alongside an FCF yield of -11.25% and ROIC of -35%, the weakest pillars in the RQD rating. Investors must weigh current valuation against -21.1% operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical/Dental Instruments (Health Care), STIM carries a macro regime beta of 1.00 and gross margin of 48.5%.
- Key Question #1: What is the composition and maturity schedule of the $65.8M debt, and how does it relate to the 2.94 Debt/Equity reading?
- Key Question #2: What were the contents and outcome of the scheduled November 4 results referenced in the news wire?
- Key Question #3: What are the company's core products, customer concentration, and revenue mix?
STIM Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Neuronetics Inc. (STIM) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 20h ago
Neuronetics Stock Price Forecast. Should You Buy STIM? StockInvest.us report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 23h ago
Neuronetics, Inc. (STIM) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Neuronetics: Transforming From Device Manufacturer To Psychedelic Infrastructure (STIM) Seeking Alpha report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views Yahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE ad-hoc-news.de • 1d ago
Neuronetics schedules November 4 results for Neuronetics stock ad-hoc-news.de report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Beta Bionics, Inc. (BBNX) Reports Q3 Loss, Beats Revenue Estimates Yahoo Finance report covering Neuronetics Inc. (STIM) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo • 12d ago
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook netwo
🟡 MARKET WIRE Yahoo • 13d ago
Integra LifeSciences (IART) Surpasses Q3 Earnings Estimates Integra (IART) delivered earnings and revenue surprises of +5.36% and -0.81%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
STIM Bull vs. Bear Conversation Board — What's Your Call at $2.06?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON STIM 🐻 33% BEARISH CONVICTION
MA MacroHawk_NYC Cross-Asset Macro Desk 🐂 BULLISH
🎯 Target: $2.81 (+24.9%)
📌 Pinned Debate Whale 13F Flow pillar at 11/20 is the rating's strongest component, reflecting institutional accumulation and options positioning.
Don't sleep on STIM's setup in Health Care. Whale 13F Flow pillar at 11/20 is the rating's strongest component, reflecting institutional accumulation and options positioning.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (28/100) backs up the fundamental quality.
EarningsSniper 🐂 BULL
Both sides have a point here — STIM's 6/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
RE RedlineAuditor Accounting Quality Watch 🐻 BEARISH
🎯 Target: $1.73 (-23.1%)
Spot @ $2.25 Altman Z of 0.2 and Debt/Equity of 2.94 sit alongside an FCF yield of -11.25% and ROIC of -35%, the weakest pillars in the RQD rating.
I respect the product at Neuronetics Inc., but the stock at $2.25 is a different story. Altman Z of 0.2 and Debt/Equity of 2.94 sit alongside an FCF yield of -11.25% and ROIC of -35%, the weakest pillars in the RQD rating.. FCF yield is -11.25% and RQD sits at 28/100 (E) — why pay up here when you can wait for next quarter's numbers?